THE CONTEMPORARY NOTIONS ABOUT PATHOGENETIC ROLE OF PODOCYTES IN DEVELOPMENT AND PROGRESSION OF DIABETIC NEPHROPATHY. THE REVIEW
DOI:
https://doi.org/10.30890/2567-5273.2024-35-00-027Keywords:
diabetic nephropathy, podocytes, podocytopathy, proteinuria, mitochondrial dysfunction, epigenetic alterations, gromerulosclerosis, nephroprotection.Abstract
The contemporary data of experimental and clinical investigations concerned a participation of podocytes in pathogenesis of diabetic nephropathy (DN) are presented in the review. A convincing confirmation of podocytes’ participation in the mechanisms ofMetrics
References
1.Agrawal S., He J.C., Tharaux P.L. Nuclear receptors in podocyte biology and glomerular disease // Nat. Rev. Nephrol. – 2021. – Vol. 17. – P. 185-204. DOI: 10.1038/s41581-020-00339-6.
Audzeyenka I., Rachubik P., Typiak M. et al. Hyperglycemia alters mitochondrial respiration efficiency and mytopathy in human podocytes // Exp. Cell Res. – 2021. – Vol. 407. – article 112758. DOI: 10.1016/j.yexcr.2021.112758.
Barutta F., Bellini S., Gruden G. Mechanisms of podocyte injury and implications for diabetic nephropathy // Clinical Science. – 2022. – Vol. 136. – P. 493-520. DOI: 10.1042/CS20210625.
Bobkova I., Chebotareva N., Schukina A. et al. New insights into the molecular mechanisms of podocyte injury in diabetes // Journal of Clinical and Experimental Nephrology. – 2018. Vol. 3, № 3. – Article 17. DOI: 10.21767/2472-5056.-100068.
Chen X., ZhaoL., Xing Y. et al. Down-regulation of microRNA-21 reduces inflammation and podocyte apoptosis in diabetic nephropathy be relieving the repression of TIMP3 expression // Biomed. Pharmacother. – 2018. – Vol. 108. – P 7-14. DOI: 10.1016/j.biopha.2018.09.007.
Daehn I.S., Duffield J.S. The glomerular filtration barrier: a structural target for novel kidney therapies // Nat. Rev. Drug Discov. – 2021. – Vol. 20. – P. 770-778. DOI: 10.1038/s41573-021-00242-0.
Eftekhari A., Vached S.Z., Kavetskyy T. et al. Cell junction proteins: crossing the glomerular filtration barrier in diabetic nephropathy // International Journal of Biological Micromolecules. – 2020. – Vol. 148. – P. 475-482. DOI: 1016/j.ijbiomac.-2020.01.168.
Fakhruddin S., Alanazi W., Jackson K.E. Diabetes induced reactive oxygen species: mechanisms of their generation and role in renal injury // J. Diabetes Res. – 2017. – Vol. 2017. – P. 1-30. DOI: 10.1155/2017/8379327.
Forbes J.M., Thorburn D.R. Mitochondrial dysfunction in diabetic kidney disease // Nar. Rev. Nephrol. – 2018. - Vol. 14. – P. 291-312. DOI: 10.1038/nrneph.2018.9.
Gil C.L., Hooker E., Larivec B. Diabetic kidney disease, endothelial damage, and podocyte-endothelial crosstalk // Kidney Medicine. – 2021. – Vol. 3, № 1. – P.105-115. DOI: 10.1016/j.xkme.2020.10.005.
Heerspink H.J.L., Parving H.H., Andress D.L. et al. Antrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomized, placebo-controlled trial // Lancet. – 2019. – Vol. 393. – P. 1937-1947. DOI: 10.1016/S0140-6736(19)30772-X.
Ishi H., Kaneko Sh., Yanai K. et al. MicroRNA in podocyte injury in diabetic nephropathy // Front. Genet. – 2020. – Vol. 11. – Article 993. DOI: 10.3389/fgene.2020.00993.
Kato M., Natarajan R. Epigenetics and epigenomics in diabetic kidney disease and metabolic memory // Nat. Rev. Nephrol. – 2019. – Vol. 15, № 6. – P. 327-345. DOI: 10.1038/s41581-019-0135-6.
Ke G., Chen X., Liao R. et al. Receptor activator of NF-kb mediates podocyte injury in diabetic nephropathy // Kidney Int. – 2021. – Vol. 100, № 2. – P. 377-390. DOI: 10.1016/j.kint.2021.04.036.
Khoury C.C., Chen S., Ziyadeh F.N. Pathophysiology of diabetic nephropathy // Chronic Renal Disease Academic Press. – 2020. – P. 279-296. DOI: 10.1016/B978-0-12-815876-0.00019-X.
Kopp J.B., Anders H.J., Susztak K. et al. Podocytopathies // Nat. Rev. Dis. Primers. – 2020. – Vol. 6, № 1. – P. 68. DOI: 10.1038/s41572-020-0196-7.
Kravets I., Mallipattu S.K. The role of podocytes and podocyte-associated biomarkers in diagnosis and treatment of diabetic kidney disease // Journal of Endocrine Society. – 2020. – Vol. 4, № 4. – P. 1-11. DOI: 10.1210/jendso/bvaa029.
Lehtonen S. Metformin protects against podocyte injury in diabetic kidney disease // Pharmaceuticals. – 2020. – Vol. 13, № 12. – Article 452. DOI: 10.3390/ph13120452.
Li S-Y., Susztak K. The role of peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) in kidney disease // Semin. Nephrol. – 2018. – Vol. 38. – P. 121-126. DOI: 10.1016/j.semnephrol.2018.01.003.
Liu S., Yuan Y., Xue Y. et al. Podocyte injury in diabetic kidney disease: a focus on mitochondrial dysfunction // Front. Cell Dev. Biol. – 2022. – Vol. 10. – e832887. DOI: 10.3389/fcell.2022.832887.
Maestroni S., Zerbini G. Diabetic nephropathy – research // Microvascular Disease in Diabetes. – 2020. – P. 97-109. DOI: 10.1002/9781119309642.ch8.
Mahtal N., Lenoir O., Tharaux P-L. Glomerular endothelial cell crosstalk with podocytes in diabetic kidney disease // Front. Med. – 2021. – Vol. 8. – Article 659013. DOI: 10.3389/fmed.2021.659013.
Nakamichi R., Hayashi K., Itoh H. Effects of high glucose and lipotoxicity on diabetic podocytes // Nutrients. – 2021. – Vol. 13. – Article 241. DOI: 10.3390/nu13010241.
Pena M.J., de Zeeuw D., Andress D. et al. The effects of antrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy // Diabetes Obes. Metab. – 2017. – Vol. 19. – P. 749-753. DOI: 10.1111/dom.12864.
Royal V., Zee J., Hu Q. et al. Ultrastructural characterization of proteinuric patients predicts clinical outcomes // J. Am. Soc. Nephrol. – 2020. – Vol. 31, № 4. – P. 841-854. DOI: 10.1681/ASN.2019080825.
Selby N.M., Taal M.W. An updated overview of diabetic nephropathy: diagnosis, prognosis, treatment goals and latest guidelines // Diabetes, Obesity and Metabolism. – 2020. – Vol. 22. – P. 3-15. DOI: 10.1111/dom.14007.
Sugita E., Hayashi K., Hishikawa A., Itoh H. Epigenetic alterations in podocytes in diabetic nephropathy // Front. Pharmacol. – 2021. – Vol. 12. – e.759299. DOI: 10.3389/fphar.2021.759299.
Sun Y., Cui S., Hou Y., Yi F. The updates of podocyte lipid metabolism in proteinuric kidney disease // Kidney Dis. – 2021. – Vol. 7. – P. 438-451. DOI: 10.1159/000518132.
Vincenzo A.D., Bettini S., Russo L. et al. Renal structure in type 2 diabetes: facts and misconceptions // Journal of Nephrology. – 2020. – Vol. 33. – P. 901-907. DOI: 10.1007/s40620-020-00797-y.
Vodosek Hojs N., Bevc S., Ekart R. et al. Oxidative stress markers in chronic kidney disease with emphasis on diabetic nephropathy // Antioxidants. – 2020. – Vol. 9, № 10. – Article 925. DOI: 10.3390/antiox9100925.
Wang J., Shen L., Hang H. et al. Antrasentan alleviates high glucose induced podocyte injury by the microRNA-21 forkhead box 01 axis // Eur. J. Pharmacol. – 2019. – Vol. 852. – P. 142-150. DOI: 10.1016/j.ejphar.2019.03.013.
Widmeier E., Airik M., Hugo H. et al. Treatment with 2,4-dihydroxybenzoic acid prevents FSGS progression and renal fibrosis in podocyte-specific Coq6Knockout mice // Jasn. – 2019. – Vol. 30. – P. 393-405. DOI: 10.1681/ASN.2018060625.
Widmeier E., Yu S., Nag A. et al. ADCK4 deficiency destabilizes the coenzyme Q complex, wich is rescued by 2,4-dihydroxybenzoic acid treatment // Jasn. – 2020. – Vol. 31. – P. 1191-1211. DOI: 10.1681/ASN.2019070756.
Zhang L., Wen Z., Han L. et al. Research progress on the pathological mechanisms of podocytes in diabetic nephropathy // Journal of Diabetes Research. – 2020. – Vol. 2020. – Article ID 7504798, 15 pages. DOI: 10.1155/2020/7504798.
Zoja C., Xinaris C., Macconi D. Diabetic nephropathy: novel molecular mechanisms and therapeutic targets // Font. Pharmacol. – 2020. – Vol. 11. – Article 586892. DOI: 10.3389/fphar.2020.586892.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Authors
This work is licensed under a Creative Commons Attribution 4.0 International License.
